It achieves antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering bacterial replication. It has good antibacterial effect on most Enterobacteriaceae, Gram-negative bacteria, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, etc., but has poor effect on anaerobic bacteria and enterococci.

In two clinical studies, it was found that simvastatin can moderately enhance the anticoagulant effect of bean-scented anticoagulants. Prothrombin time should be checked frequently before early anticoagulant therapy and simvastatin use in adults to determine whether there is a significant change in prothrombin time. When patients taking bean-scented derivatives have a stable prothrombin time, it is recommended to continue monitoring prothrombin time for a fixed period of time. If the dose of simvastatin is changed, the above procedure should be followed. In patients not taking anticoagulants, simvastatin treatment has never been reported to affect bleeding or prothrombin time.

By inhibiting bacterial DNA gyrase and topoisomerase IV, it inhibits bacterial DNA replication, transcription and repair processes. It has antibacterial activity against most strains of the following microorganisms: 1. Gram-positive bacteria: Staphylococcus aureus (limited to strains sensitive to methicillin), Streptococcus pneumoniae (strains sensitive to penicillin). 2. Gram-negative bacteria: Escherichia coli, Haemophilus influenzae and parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae, Proteus mirabilis. 3. Other microorganisms: Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae.

In vivo, it competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. Its main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. This product also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.

Levetiracetam is a pyrrolidone derivative whose chemical structure is not related to existing antiepileptic drugs. The antiepileptic effect of levetiracetam has been evaluated in a variety of epilepsy animal models. Protective effects were observed on generalized seizures secondary to focal seizures induced by pilocarpine and kainic acid, and it had an inhibitory effect on both the kindling process and the kindling state in the rat kindling model of complex partial seizures.